Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure

By C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt. Circulation, 2005

633 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). (2013, background): “107 Lower fat mass in PEW increases circulating adiponectin, causing adiponectin to lose its association with mortality after adjustment for BMI in diseases such as CHF.”
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “In accordance, recent reports have shown that patients with moderate to severe CKD are at a high risk of developing congestive heart failure (CHF) (11) and that the majority of these patients have coronary heart disease or risk equivalents (12).”
Cardiac remodeling in obesity. (2008, background): “In relation to the role of adiponectin in the obesity paradox, it was found that a high circulating adiponectin level was a predictor of mortality in patients with congestive heart failure (179).”